|

Pembrolizumab (KEYTRUDA® ) Clinical Trials

13 actively recruiting trials across 12 locations

Also known as: KEYTRUDA®, Pembrolizumab

Other1 trial

Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer
Phase 2

Birmingham, Alabama1 trial

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

Site # 0137

Phase 2/3

Dothan, Alabama1 trial

A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

XCancer Research Network/Dothan Hematology & Oncology

Phase 1/2

Chandler, Arizona1 trial

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

Ironwood Cancer & Research Centers

Phase 2/3

Scottsdale, Arizona1 trial

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Honor Health Research Institute

Phase 1/2

San Diego, California1 trial

A Beta-only IL-2 ImmunoTherapY Study

Sharp Memorial Hospital

Phase 1/2

San Francisco, California1 trial

A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

UCSF Helen Diller Family Comprehensive Cancer Center

Phase 1

Stanford, California1 trial

Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer

Stanford University

Phase 1

New Haven, Connecticut1 trial

Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

Yale

Phase 2

Louisville, Kentucky1 trial

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

Norton Cancer Institute - Audubon

Phase 3

Bethesda, Maryland1 trial

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

National Institutes of Health Clinical Center

Phase 2

Morristown, New Jersey1 trial

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

Morristown Medical Center

Phase 1/2

New York, New York1 trial

GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors

Tisch Cancer Institute (TCI), Icahn School of Medicine

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.